Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Melody A. Cobleigh"'
Autor:
Virginia Paton, Gracie Lieberman, Melody A. Cobleigh, Debasish Tripathy, Nicholas J. Robert, Charles L. Vogel, Louis Fehrenbacher, Janet M. Wolter, Steven Shak, Susy Scholl, Dennis J. Slamon
Publikováno v:
Journal of Clinical Oncology. 41:1501-1510
PURPOSE Overexpression of the HER2 protein occurs in 25% to 30% of human breast cancers and leads to a particularly aggressive form of the disease. Efficacy and safety of recombinant humanized anti-HER2 monoclonal antibody as a single agent was evalu
Autor:
Sara A. Hurvitz, Anne Morris, Melody A. Cobleigh, Sandra M. Swain, Hope S. Rugo, Haocheng Li, Peter A. Kaufman, Joyce O'Shaughnessy, Denise A. Yardley, Debu Tripathy, Ginny Mason, Adam Brufsky, Mohammad Jahanzeb, Vincent Antao
Publikováno v:
Breast Cancer Research and Treatment. 188:179-190
Systemic Therapies for HER2-Positive Metastatic Breast Cancer Study (SystHERs, NCT01615068) was a prospective, observational disease registry designed to identify treatment patterns and clinical outcomes in patients with HER2-positive metastatic brea
Autor:
Vincent Antao, Mohammad Jahanzeb, Denise A. Yardley, Joyce O'Shaughnessy, Peter A. Kaufman, Ginny Mason, Adam Brufsky, Sara A. Hurvitz, Laura Chu, Melody A. Cobleigh, Hope S. Rugo, Sandra M. Swain, Debu Tripathy, Haocheng Li
Publikováno v:
Clinical Cancer Research. 26:1105-1113
Purpose: We report treatments and outcomes in a contemporary patient population with HER2-positive metastatic breast cancer (MBC) by hormone receptor (HR) status from the Systemic Therapies for HER2-positive Metastatic Breast Cancer Study (SystHERs).
Autor:
Melody A. Cobleigh, Najor, A McDonald, Louis Fogg, Sanja Turturro, Abde M. Abukhdeir, Andrew Armstrong
Publikováno v:
Cancer Research. 78:P2-09
Background: Approximately 15-20% of breast cancers overexpress HER2. These patients are eligible for trastuzumab in combination with chemotherapy. However, some patients are extreme responders to single agent trastuzumab and we wanted to identify dif
Autor:
Do-Youn Oh, Elena Elimova, Jordi Rodon, Todd E. Gray, Funda Meric-Bernstam, Rose Lai, Erika Hamilton, Melody A. Cobleigh, Gerry Rowse, Yoon-Koo Kang, Christos Vaklavas, Jaffer A. Ajani, Jose I. Mayordomo, Diana L. Hanna, Jorge Chaves, Jeeyun Lee
Publikováno v:
Molecular Cancer Therapeutics. 18:B001-B001
Background: Up to 30% of gastroesophageal adenocarcinoma (GEA) overexpress HER2. ZW25 is a novel bispecific antibody that targets HER2 domains ECD2 and ECD4, resulting in multiple differentiated and unique mechanisms of action, including increased an
Autor:
James N. Ingle, George Thomas Budd, William C. Wood, Silvana Martino, Melody A. Cobleigh, Larry Norton, Mark L. Graham, Ruta D. Rao, Robert Gray
Publikováno v:
Medical Oncology. 28:39-47
Fenretinide and tamoxifen have additive antitumor effects preclinically. We performed a randomized, placebo-controlled, double-blind adjuvant trial in breast cancer patients treated for 5 years with tamoxifen, with or without fenretinide. Between Oct
Autor:
Melody A. Cobleigh, Susan Moore
Publikováno v:
Seminars in Oncology Nursing. 23:37-45
Objectives To review the chemotherapy and targeted biologic options for treatment of advanced and metastatic breast cancer. Data Sources Clinical and research articles and textbook chapters. Conclusion Recent clinical research has led to the use of n
Autor:
Dennis J. Slamon, Mansoor N. Saleh, Stanford J. Stewart, Joanne E. Mortimer, Andrew Arnold, Debasish Tripathy, Melody A. Cobleigh, M. Murphy
Publikováno v:
Journal of Clinical Oncology. 22:1063-1070
Purpose In a pivotal phase III trial, the addition of trastuzumab to chemotherapy significantly improved response rate, time to disease progression, and overall survival in women with HER2 overexpressing metastatic breast cancer. We conducted an exte
Autor:
Stanford J. Stewart, Michael Burchmore, Steven Shak, M. Murphy, William Novotny, Dennis J. Slamon, Louis Fehrenbacher, John Gutheil, Lyndsay Harris, Debasish Tripathy, Melody A. Cobleigh, Charles L. Vogel
Publikováno v:
European Journal of Cancer. 37:25-29
Following confirmation of the appropriate dosage, safety and potential efficacy of Herceptin(trastuzumab) in small-scale phase I and II trials involving patients with refractory disease, a large trial was conducted in 222 patients with breast cancer
Autor:
J Wolter, Korenblit Ad, Bruce C. McLeod, S G Taylor th, Carol M. Richman, Melody A. Cobleigh, Sharon Manson, Leonard A. Valentino, Richard G. Ghalie, Adler Ss
Publikováno v:
Journal of Clinical Oncology. 12:342-346
PURPOSE We investigated the role of high-dose chemotherapy and autologous bone marrow transplantation (ABMT) as the initial systemic treatment in patients with hormone-unresponsive metastatic breast cancer. We studied a regimen involving a split-cour